Stage 1: History & Presentation (Timestamp: 2 Months Prior to Admission)
A 68-year-old male retired engineer (residing in Delhi NCR, 40-pack-year smoking history, history of HTN, HLD, CAD, AFib) presents to the emergency department with a 2-month history of subacute progressive cognitive decline, aphasia, confusion, and recurrent focal neurological deficits.
HPI:
- 2 Months Ago: First presented with acute aphasia. Brain MRI revealed multiple small acute infarcts in bilateral frontal lobes, right internal capsule, and right middle cerebellar peduncle. Diagnosed as cardioembolic s/p AFib and started on Apixaban + Aspirin.
- 4 Days Later: Represented with recurrent mild aphasia and progressive confusion. Antihypertensives discontinued for suspected hypoperfusion.
- 3 Weeks Later: Re-admitted with worsening lethargy, confusion, gait instability, and urinary incontinence. Repeat MRI showed new bilateral cerebral infarcts in the centrum semiovale and corona radiata. Systemic CT revealed a 1.7 cm spiculated lung mass and a left renal lesion.
- Presenting Event: Represented 5 days later with severe dysphagia, progressive confusion, right facial droop, and right hemiparesis despite therapeutic Enoxaparin.
Hello, Chief Resident here.
Key Findings:
* 68-year-old male smoker with AFib presenting with subacute, progressive cognitive decline and recurrent, multi-territory acute ischemic strokes refractory to Apixaban and Enoxaparin.
* Systemic imaging showing a 1.7 cm spiculated lung mass and a left renal lesion.
Differential Diagnoses:
1. Trousseau Syndrome / Malignancy-Associated Hypercoagulability with NBTE (50%): Unifies recurrent embolic strokes failure on therapeutic anticoagulation with a suspicious pulmonary lesion.
2. Primary/Secondary CNS Vasculitis (20%): Explains multifocal infarcts, encephalopathy, and subacute progression; could be paraneoplastic.
3. Intravascular Large B-Cell Lymphoma (15%): Classic mimic of multifocal strokes, subacute dementia, and organ lesions.
4. Infective Endocarditis or Resistant Cardioembolism (15%): Underlying AFib, but breakthrough strokes on therapeutic LMWH strongly suggest marantic (NBTE) or bacterial vegetations.
Recommended Tests:
1. Transesophageal Echocardiogram (TEE): To evaluate for non-bacterial thrombotic endocarditis (NBTE) vs. bacterial vegetations.
2. Biopsy of Lung Mass / Bronchoscopy: To confirm suspected underlying malignancy.
3. Lumbar Puncture: CSF analysis for protein, cytology, flow cytometry, and paraneoplastic/infectious panels.
4. Coagulation & DIC Screen: D-dimer, fibrinogen, and antiphospholipid panel.
5. High-Resolution Vessel Wall MRI or Brain DSA: To evaluate for CNS vasculitis.
Hello Attending Consultant here
Critique: Solid prioritization of malignancy-driven hypercoagulability, but overweights primary CNS vasculitis (low pretest without systemic inflammatory signs) and underemphasizes need for immediate tissue diagnosis. TEE first is appropriate; DSA premature before LP/cytology.
Top 3 DDx:
1. Trousseau syndrome/NBTE secondary to lung adenocarcinoma
2. Intravascular large B-cell lymphoma
3. Septic emboli from culture-negative endocarditis
Specific points:
1. Expedite CT-guided lung biopsy + PET-CT staging before further neurovascular imaging.
2. Add blood cultures ×3 and serum β2-microglobulin/LDH now.
3. TEE with bubble study + look specifically for valvular stranding.
4. LP: include EBV PCR and flow cytometry (hold DSA).
5. Switch to continuous UFH infusion pending biopsy; avoid antiplatelets.
6. Repeat MRI with DWI/SWI to quantify burden and microbleeds.
7. Oncology/hematology consult same-day for empiric consideration of steroids if IVL suspected.
Stage 2: Diagnostic Workup Results (Hospital Days 1–7)
Echocardiography:
* TEE: No valvular vegetations, no intracardiac thrombus, no PFO on bubble study. Mild concentric LVH. NBTE effectively excluded at imaging resolution.
Coagulation/DIC Screen:
* D-dimer: 9,200 ng/mL (markedly elevated, rising from 6,100 on admission)
* Fibrinogen: 165 mg/dL (low-normal, downtrending); Platelets: 118k → 96k over 5 days
* INR/aPTT: therapeutic on UFH infusion; Factor VIII normal
* Antiphospholipid panel (LA, aCL, anti-β2GPI): Negative ×2
* Interpretation: Chronic compensated DIC / hypercoagulable state
Infectious/Inflammatory:
* Blood cultures ×3: Negative at 96 hours
* ESR 38, CRP 4.2 mg/dL (mildly elevated); procalcitonin negative
CSF Analysis (Day 3):
* Protein 92 mg/dL, glucose normal, WBC 4 (lymphocytic)
* Cytology ×2: Negative; Flow cytometry: Negative; EBV PCR: Negative
* Paraneoplastic/autoimmune encephalitis panel: Pending
Vascular Imaging:
* Vessel wall MRI: No arterial wall enhancement
* DSA: Multifocal distal branch occlusions, embolic pattern; no beading or vasculitis
* CTA chest: No complex aortic arch atheroma
Tissue Diagnosis:
* CT-guided lung biopsy (Day 4): Moderately differentiated lung adenocarcinoma, TTF-1 positive, KRAS G12C mutated, PD-L1 40%
* PET-CT: FDG-avid lung mass and renal lesion (likely synchronous primary or metastasis); no nodal disease; no lymphadenopathy to suggest lymphoma
Hematologic Markers:
* LDH 310 (mildly elevated), β2-microglobulin normal, peripheral smear: schistocytes rare, no blasts — argues against IVL
Repeat Brain MRI (Day 6):
* New bilateral embolic infarcts despite therapeutic UFH infusion (aPTT 70–80s)
* SWI: 8–10 scattered cortical microbleeds
Current Status (Day 7): Patient remains encephalopathic with fluctuating right hemiparesis. Family asking about goals of care. Oncology recommends staging workup; Neurology notes worsening exam despite maximal anticoagulation.
Stage 2: Physical & Neurological Examination (Timestamp: Admission / Day 1)
Physical Exam: T 36.8°C (afebrile), HR 76 bpm (irregularly irregular / AFib), BP 158/75 mmHg, RR 16/min, SpO2 98% room air. Lungs clear. Heart: No murmurs or friction rubs.
Neurological Exam: Alert, oriented x 2, slow processing speed, fluent speech with complex command difficulty. Right central facial palsy, right pronator drift, mild right hemiparesis (4+/5 power).
Initial Laboratory Evaluation:
- Hemogram: WBC 8.4 x 10³/µL, Hb 12.7 g/dL, Platelets 210,000/µL.
- Biochemistry & Inflammatory Markers: Normal renal/liver function. ESR 15 mm/hr (normal), D-dimer elevated (912 ng/mL).
- Autoimmune & Hypercoagulable Serologies: ANA Positive (1:160), Anti-Cardiolipin, Beta-2 Glycoprotein I, Lupus Anticoagulant negative.
Hello, Chief Resident here.
Updated Key Findings:
* Confirmed primary lung adenocarcinoma (KRAS G12C+, PD-L1 40%) with metastatic/synchronous renal lesion.
* Recurrent multifocal embolic strokes refractory to therapeutic UFH.
* Laboratory-confirmed cancer-associated chronic compensated DIC (dramatically rising D-dimer to 9,200 ng/mL, downtrending platelets, low-normal fibrinogen).
* Negative DSA and vessel-wall MRI rule out primary CNS vasculitis.
Differential Diagnoses:
1. Trousseau Syndrome / Cancer-Associated Hypercoagulability (with occult/microscopic NBTE): 85% — Confirmed adenocarcinoma directly driving subclinical DIC and embolic microthrombi refractory to UFH; TEE often misses sub-millimeter vegetations.
2. Tumor Embolism / Paraneoplastic Microvascular Thrombosis: 10% — Direct vascular occlusion by circulating tumor aggregates or microthrombi.
3. Paraneoplastic Vasculopathy / Coagulopathy: 5% — Persistent hypercoagulable cascade despite standard heparin dosing.
Prioritized Next Steps & Management:
1. Goals of Care / Palliative Care Consultation: Conduct urgent family meeting given rapid neurological decline despite maximal anticoagulation.
2. Expedite Systemic Cancer Therapy: Initiate oncology-directed therapy (e.g., targeted KRAS G12C inhibitor or chemo-immunotherapy) immediately; treating the underlying malignancy is the only definitive cure for Trousseau syndrome.
3. Anticoagulation Optimization: Transition from UFH to high-dose therapeutic LMWH (Enoxaparin/Dalteparin), which is superior for mucin-producing adenocarcinoma-associated hypercoagulability.
4. Serial DIC Panels: Track D-dimer, fibrinogen, and platelets every 24–48 hours to assess biological response.
Hello Attending Consultant here
Critique: Early exam data (normal ESR, modest D-dimer, ANA 1:160 isolated, no murmur) appropriately de-emphasizes acute IE/vasculitis, yet Resident plans that delay tissue diagnosis or persist with antiplatelets risk missing Trousseau driver. Anticoagulation switch alone insufficient without oncologic control.
Top 3 DDx:
1. Trousseau/NBTE from occult lung adenocarcinoma
2. Cardioembolic (AFib) with breakthrough hypercoagulability
3. Intravascular lymphoma (less likely given smear/ESR)
Specific points:
1. Immediate CT chest/abdomen to characterize spiculated mass/renal lesion.
2. TEE + serial blood cultures before escalating AC.
3. Plasma D-dimer/fibrinogen trend q48h; initiate UFH bridge.
4. Hold aspirin; avoid empiric steroids.
5. LP only after imaging excludes mass effect; add cytology/flow.
6. PET-CT + biopsy within 48 h—definitive therapy targets malignancy.
7. Early goals-of-care discussion given progressive deficits.
Hello, Expert Clinician here.
Unifying Diagnosis: Trousseau syndrome — lung adenocarcinoma–driven hypercoagulability with marantic (non-bacterial thrombotic) microemboli, causing recurrent multi-territory strokes refractory to apixaban, LMWH, and UFH. The compensated DIC (D-dimer 9,200, falling platelets/fibrinogen) and biopsy-proven adenocarcinoma seal it.
Differentials:
- Occult NBTE: Fits perfectly; negative TEE does not exclude sub-millimeter vegetations — this is likely the embolic source.
- Cardioembolic AFib: Plausible initially, but fails on therapeutic anticoagulation; AFib is a red herring anchoring early teams.
- Tumor emboli: Possible but rare without cardiac/pulmonary vascular invasion.
- IVL/vasculitis: Excluded by bland CSF, negative flow cytometry, normal smear, and clean DSA/vessel-wall MRI.
Key Pivot: New infarcts despite therapeutic UFH — anticoagulation failure in multi-territory emboli with exploding D-dimer redirects from "stroke management" to "treat the cancer."
Next Move: Urgent systemic therapy (KRAS G12C–directed or chemo-immunotherapy) is the only disease-modifying intervention; continue LMWH, hold antiplatelets, and address goals of care given accumulating burden.
Teaching Pearl: Embolic strokes of undetermined source that break through therapeutic anticoagulation — especially with markedly elevated D-dimer — mandate an occult malignancy workup; in Trousseau syndrome, you cannot out-anticoagulate an untreated tumor.
Stage 3: Neuro-Thoracic Imaging, CSF & Cardiac Diagnostic Workup (Timestamp: Hospital Days 1-3)
Diagnostic Workup:
- Brain MRI & CTA:
- Serial MRIs demonstrate numerous scattered small Foci of restricted diffusion (acute/subacute multifocal infarcts) involving bilateral cerebral hemispheres (centrum semiovale, thalamus, frontal/parietal lobes) and cerebellum.
- Extensive, progressive, confluent periventricular and subcortical white matter T2/FLAIR hyperintensities (progressive leukoencephalopathy).
- CTA Head/Neck: Mild multifocal atherosclerotic luminal narrowing without major vessel occlusion.
- Echocardiogram & Blood Cultures: Echo negative for cardiac thrombus, vegetations, PFO, or valvular lesions. Blood cultures negative (2x).
- CSF Analysis: Lumbar puncture demonstrates mild lymphocytic pleocytosis (WBC 14/µL), elevated protein (84 mg/dL), normal glucose. CSF cytology and viral/bacterial PCRs negative.
- Systemic Imaging & Biopsy: Chest CT confirms a 1.7 cm spiculated lung nodule with hilar lymphadenopathy. Transbronchial lung biopsy confirms Metastatic Lung Adenocarcinoma (Stage IV).
Hello, Chief Resident here.
Key Findings:
* Confirmed Stage IV Metastatic Lung Adenocarcinoma with hilar lymphadenopathy.
* Brain MRI showing progressive, multifocal acute/subacute ischemic strokes across multiple vascular territories with confluent leukoencephalopathy.
* CSF pleocytosis (WBC 14) and elevated protein (84 mg/dL); negative infectious, cytological, and cardiac workups.
Differential Diagnoses:
1. Trousseau Syndrome with Microscopic NBTE (85%): Hypercoagulability secondary to mucin-producing adenocarcinoma driving microthrombi and DIC; sub-millimeter valvular vegetations often elude echocardiography.
2. Tumor Microembolism (10%): Direct microvascular embolization by circulating adenocarcinoma aggregates.
3. Paraneoplastic CNS Vasculopathy / Encephalopathy (5%): Explains mild CSF pleocytosis, elevated protein, and confluent leukoencephalopathy.
Prioritized Management Steps:
1. Immediate Systemic Cancer Therapy: Initiate targeted therapy (KRAS G12C inhibitor or chemo-immunotherapy); treating the underlying malignancy is the only definitive way to arrest Trousseau syndrome.
2. Optimize Anticoagulation: Transition to weight-adjusted therapeutic LMWH (or continuous UFH), as DOACs frequently fail in cancer-associated mucinous thrombosis.
3. Serial DIC Monitoring: Track D-dimer, fibrinogen, and platelets every 24–48 hours to assess prothrombotic control.
4. Goals-of-Care Conference: Urgent discussion with family regarding guarded prognosis given Stage IV cancer and severe, progressive neurological deficits.
Hello Attending Consultant here
Critique: Resident correctly anchors on Trousseau but overstates CSF pleocytosis as paraneoplastic (nonspecific; common in embolic burden). Delays in KRAS-directed therapy and LMWH transition risk further infarcts; leukoencephalopathy warrants SWI review for microbleeds before AC escalation.
Top 3 DDx:
1. Trousseau syndrome/NBTE from Stage IV lung adenocarcinoma
2. Tumor microemboli
3. Hypercoagulable leukoencephalopathy (cancer-DIC driven)
Specific points:
1. Start sotorasib (KRAS G12C) + pembrolizumab same-day; biopsy already confirmatory.
2. Switch to therapeutic dalteparin 200 IU/kg; monitor anti-Xa.
3. Repeat MRI DWI/SWI q48h to track new lesions/microbleeds.
4. Serial DIC panel (D-dimer/fibrinogen/plts) q24h.
5. Hold further LP/DSA; yield exhausted.
6. Palliative care + goals-of-care huddle within 24 h.
7. Add VTE prophylaxis stockings; avoid IVC filter.
Hello, Expert Clinician here.
Unifying Diagnosis: Trousseau syndrome from Stage IV lung adenocarcinoma — mucin-mediated hypercoagulability with marantic microemboli causing progressive multifocal infarcts, leukoencephalopathy, and DIC refractory to anticoagulation. CSF pleocytosis is reactive, not paraneoplastic encephalitis.
Differentials:
- Occult NBTE: Highly likely embolic source; echo-negative doesn't exclude microscopic vegetations — fits perfectly.
- Cardioembolic AFib: Untenable — strokes recur despite therapeutic UFH; anchoring trap.
- Tumor microemboli: Plausible co-contributor given stage IV disease; not independently testable.
- Paraneoplastic vasculopathy/IVL: Effectively excluded — bland cytology, negative flow, clean DSA, no smear abnormalities.
Key Pivot: Hilar lymphadenopathy + biopsy-proven adenocarcinoma transforms "ESUS with AFib" into malignancy-driven coagulopathy; the leukoencephalopathy pattern (not purely embolic) signals diffuse microvascular thrombosis — a grave prognostic marker.
Next Move: Same-day KRAS-directed systemic therapy is the only intervention capable of arresting the prothrombotic cascade; escalate dalteparin, trend DIC markers, and urgently address goals of care.
Teaching Pearl: In cancer-associated stroke, progressive white matter disease alongside multifocal DWI lesions reflects cerebral microthrombosis — anticoagulation alone cannot outpace an untreated mucinous tumor.
Stage 4: Progressive Clinical Course & Therapeutic Refractoriness (Timestamp: Hospital Days 4-10)
Hospital Course:
- Patient experienced relentless, progressive neurological deterioration with new multifocal stroke recurrences despite maximal therapeutic anticoagulation (IV Heparin / Enoxaparin) and antiplatelet therapy.
- Development of hypoxemia and pulmonary embolism (PE). Empiric pulse corticosteroids (IV Methylprednisolone) initiated for suspected cerebral vasculitis/arteriopathy.
- Progression to severe encephalopathy and respiratory failure, leading to palliative comfort care and peaceful expiration.
Hello, Chief Resident here.
Updated Key Findings:
* Stage IV lung adenocarcinoma complicated by fulminant, refractory Trousseau syndrome.
* Recurrent multifocal cerebral microinfarcts and new pulmonary embolism despite therapeutic anticoagulation (IV Heparin/LMWH) and antiplatelets.
* Rapid progression to severe encephalopathy and fatal respiratory failure.
Differential Diagnoses:
1. Trousseau Syndrome / Occult NBTE (90%): Mucin/tumor-driven hypercoagulability and DIC causing recalcitrant systemic and cerebral microemboli refractory to anticoagulation.
2. Tumor Microembolism with Microvascular DIC (8%): Direct intravascular occlusion by circulating tumor cell aggregates alongside fulminant prothrombotic cascades.
3. Paraneoplastic CNS Vasculopathy (2%): Complete lack of response to pulse methylprednisolone confirms microvascular thrombosis rather than primary autoimmune inflammation.
Recommended Next Steps:
1. Post-Mortem Histopathology (Autopsy): Evaluate cardiac valves for sub-millimeter non-bacterial thrombotic endocarditis (NBTE) and confirm cerebral microvascular thrombotic occlusion.
2. Morbidity and Mortality (M&M) Review: Analyze key decision points, emphasizing early recognition of Trousseau syndrome in embolic stroke of undetermined source (ESUS) accompanied by markedly elevated D-dimer levels.
Hello Attending Consultant here
Critique: Post-mortem focus is apt given fatal course, but Resident underplays autopsy yield on microvascular histology and over-relies on M&M without specifying actionable earlier pivots (e.g., day-1 PET/biopsy). Steroids were futile—correctly deprioritized.
Top 3 DDx:
1. Fulminant Trousseau/NBTE from Stage IV lung adenocarcinoma
2. Tumor microemboli + DIC
3. Refractory cancer-associated PE/stroke cascade
Specific points:
1. Prioritize autopsy: valves (micro-NBTE), brain (fibrin thrombi vs tumor emboli), lung primary.
2. M&M: Highlight D-dimer >5000 + ESUS as malignancy red flag—mandate CT chest <24h.
3. Avoid empiric steroids in confirmed adenocarcinoma hypercoagulability.
4. Document AC failure metrics (anti-Xa/aPTT) for future protocols.
5. Family debrief: emphasize irreversible microvascular burden.
6. Tumor board review: KRAS G12C therapy timing as missed disease-modifier.
7. Publish as teaching case on anticoagulation-refractory Trousseau.
Hello, Expert Clinician here.
Final Unifying Diagnosis: Fulminant Trousseau syndrome — Stage IV lung adenocarcinoma driving mucin-mediated hypercoagulability, decompensated DIC, and occult NBTE/tumor microemboli, producing refractory cerebral infarcts, leukoencephalopathy, and PE.
Differentials:
- Occult NBTE: Fits perfectly — explains echo-negative but relentless emboli; autopsy likely confirmatory.
- Cardioembolic AFib: Fully refuted — strokes progressed on therapeutic heparin; a costly anchoring error in early presentations.
- CNS vasculitis: Steroid-refractory course and clean DSA definitively exclude it; the empiric steroid trial was a diagnostic distractor.
- Tumor microemboli: Plausible co-driver; indistinguishable from marantic thrombi premortem.
Key Pivot: Multifocal strokes breaking through therapeutic anticoagulation with markedly elevated D-dimer should have triggered occult malignancy search on day 1 — the "treat the tumor, not the clot" inflection was missed.
Next Move: Autopsy with valve and cerebral microvascular histology; M&M codifying D-dimer–driven malignancy screening in ESUS.
Teaching Pearl: Trousseau syndrome is a hematologic emergency, not a stroke subtype — once anticoagulation fails and microvascular leukoencephalopathy emerges, only early oncologic therapy alters trajectory; anticoagulation alone is palliative.
Stage 5: Post-Mortem Neuropathologic Confirmation (Timestamp: Autopsy & Final Diagnosis)
Neuropathology Findings:
- Multifocal cerebral and cerebellar ischemic infarcts of varying ages (ranging from acute macrophage-rich lesions to remote cavitating infarcts).
- Vascular Histopathology: Small and medium cerebral arteries demonstrate mural T-cell (CD3+) and macrophage (CD68+) predominant perivascular and transmural lymphocytic vasculitis with vessel wall thickening and luminal destruction, present both within and away from infarcts.
- Crucial Negative Pathology: Complete absence of metastatic carcinoma tumor cells or carcinomatous meningitis in the brain parenchyma or leptomeninges.
Final Unifying Diagnosis: Paraneoplastic Central Nervous System (CNS) Vasculitis secondary to Metastatic Lung Adenocarcinoma.
Hello, Chief Resident here.
Updated Key Findings:
* Post-mortem brain histology revealed mural T-cell (CD3+) and macrophage (CD68+) predominant perivascular/transmural vasculitis with luminal destruction.
* Complete absence of tumor cells, carcinomatous meningitis, or microvascular tumor emboli in brain tissue.
* Final Diagnosis: Paraneoplastic CNS Vasculitis secondary to Metastatic Lung Adenocarcinoma.
Probability-Based Diagnoses (Post-Mortem Confirmed):
1. Paraneoplastic CNS Vasculitis (100%): Histologically proven transmural lymphocytic vasculitis directly secondary to underlying lung adenocarcinoma, causing progressive multifocal strokes and steroid-refractory encephalopathy.
Key Clinical Takeaways:
1. Rare Entity Recognition: Paraneoplastic CNS vasculitis can perfectly mimic Trousseau syndrome and NBTE, presenting with multi-territory infarcts, elevated D-dimers, and refractory neurovascular decline.
2. Imaging Limitations: Angiography (DSA) and vessel-wall MRI can be false-negative in small-vessel paraneoplastic vasculitis; high-dose pulse immunosuppression combined with immediate systemic cancer therapy remains the only theoretical disease-modifying strategy.
3. M&M Learning: Highlights the diagnostic challenge of differentiating paraneoplastic immune-mediated vasculopathy from hypercoagulable states in occult malignancy.
Hello Attending Consultant here
Critique: Resident correctly pivots to autopsy-proven paraneoplastic vasculitis but under-critiques premortem anchoring on Trousseau (missed steroid-responsive window) and overstates DSA/VW-MRI sensitivity for small-vessel disease. Empiric steroids were appropriately trialed yet too late; earlier biopsy-driven immuno-oncology could have altered course.
Top 3 DDx (retrospective):
1. Paraneoplastic CNS vasculitis (lung adenoCA)
2. Trousseau/NBTE with secondary vasculopathy
3. Primary angiitis of CNS (paraneoplastic trigger)
Specific points:
1. Autopsy: Quantify vessel caliber involvement and exclude amyloid/β-A4.
2. M&M: Flag D-dimer elevation + CSF pleocytosis as dual hypercoagulable/inflammatory red flags mandating early empiric steroids + biopsy.
3. Retest archived serum/CSF for onconeural Abs (anti-Hu, CRMP5).
4. Protocolize PET + lung biopsy <48h in ESUS + mass.
5. Avoid AC escalation once vasculitis suspected; prioritize immunosuppression + KRAS therapy.
6. Family debrief: Emphasize rare immune-mediated mimicry.
7. Case report: Highlight false-negative angio in paraneoplastic small-vessel vasculitis.
Hello, Expert Clinician here.
Final Unifying Diagnosis: Paraneoplastic CNS vasculitis secondary to metastatic lung adenocarcinoma — autopsy-proven CD3+/CD68+ transmural vasculitis of small/medium cerebral arteries, mimicking Trousseau syndrome with multifocal infarcts and DIC-like markers.
Differentials:
- Trousseau/NBTE: Compelling fit — multifocal emboli, D-dimer surge, AFib, anticoagulation failure — but autopsy refutes it; hypercoagulability was likely secondary to vasculitis-driven coagulation cascade.
- Primary angiitis of CNS: Histologically identical; adenocarcinoma serves as the immune trigger — distinction semantic.
- Cardioembolic AFib: Seductive early anchor; refractoriness to anticoagulation should have prompted earlier reconsideration.
- IVL: Appropriately excluded by bland cytology, smear, and autopsy absence of intravascular tumor.
Key Pivot: CSF pleocytosis + elevated protein alongside embolic-pattern strokes was the underweighted clue — "Trousseau" doesn't cause lymphocytic CSF. Dual hypercoagulable and inflammatory markers demanded earlier empiric immunosuppression with concurrent oncologic therapy.
Next Move: Publish as a teaching case; institutionalize CSF-driven dual-pathway evaluation (vasculitis + malignancy) in refractory ESUS.
Teaching Pearl: In cancer-associated stroke with CSF inflammation, never assume pure thrombosis — paraneoplastic vasculitis wears Trousseau's mask, and steroids plus tumor therapy, not anticoagulation alone, are the only chance.